The economics of psychedelic-assisted therapies: A research agenda
Frontiers in Psychiatry December 5, 2022 Elliot Marseille, Stefano Bertozzi, James G Kahn 51 citations
Psychiatry is seeing renewed interest in using psychedelic drugs to treat mental health disorders like depression, PTSD, and addictions, with clinical evidence showing substantial potential. New therapies could become available by 2024 for patients who do not respond to traditional treatments. However, research on economic factors such as costs, cost-effectiveness, pricing, and the economic effects of widespread implementation has lagged. These issues are critical for making psychedelic therapies widely accessible. The authors describe six types of economic analyses relevant to decisions and planning, including the needs of healthcare payers, and outline desirable features of such research, including scientific rigor, long-term horizons, equity, and a global perspective.